SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as crude prices climb amid fears of Middle East supply disruptions, especially attacks and threats affecting shipping around the Strait of Hormuz, alongside risks to oil infrastructure. Traders are split between viewing the supply concerns as support for further gains and expecting a pullback if tensions ease or the rally fades.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

Discussion is dominated by GameStops warrants nearing expiration, with the shares below the exercise price and holders debating whether the warrants will expire worthless. Bears criticize Cohen and doubt an extension or catalyst will arrive, while bulls speculate he may take action; some also view unused warrants as avoiding dilution.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A tech-led rebound in the Nasdaq has sparked volatile trading, with traders debating whether the sharp bounce can hold or is a bull trap. AI infrastructure spending and debt concerns, rising oil prices, and upcoming megacap earnings are keeping sentiment divided.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

Hot inflation readings and higher-rate concerns have weighed on rate-sensitive small caps, with traders highlighting IWMs technical weakness and heavy demand for puts. The community is split between expecting an oversold bounce or rotation into small caps and anticipating further declines if support fails.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras is drawing attention amid a steep post-IPO selloff, with traders citing the analyst price-target cut, IPO lockup share releases and concerns about insider selling, alongside broader weakness in AI hardware. Bulls see an oversold opportunity and point to its wafer-scale technology, while bears question its valuation, ability to scale and reliance on OpenAI.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcoms weak share performance is drawing attention amid a broader semiconductor selloff and concerns about AI spending, financing, and returns; many traders also say CEO Hock Tans casino remarks worsened sentiment. The 10-year NTT DOCOMO VMware agreement is cited as positive news, but traders disagree on whether the deal or strong AI-growth expectations can offset the sector and valuation concerns.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is drawing attention after a sharp AI-infrastructure selloff and a volatile rebound, with traders debating whether the bounce can hold or is another bull trap. Concerns about neocloud financing needs and cash flowespecially amid sector-wide debt worriescompete with confidence that long-term demand for AI compute remains strong.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the Advanced Technology Solutions (ATS) and Connectivity and Cloud Solutions (CCS) segments. The ATS segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The CCS segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celesticas equity offering to fund expansion has been a major focus, with traders debating the dilution and the sharp, volatile pullback it accompanied. That concern contrasts with bullish views that AI data-center and networking demand, raised guidance, and expected earnings growth support buying the dip.

Lam Research Corp. engages in the design, manufacture, marketing, refurbishment, and provision of semiconductor processing equipment used in the fabrication of integrated circuits. It operates through the following geographical segments: United States, China, Europe, Japan, Korea, Southeast Asia, and Taiwan. The company was founded by David K. Lam in 1980 and is headquartered in Fremont, CA.

Lam Research Corp.

Lam Research is drawing attention ahead of its upcoming earnings report, as traders weigh the results and guidance against a sharp pullback in semiconductor equipment stocks. Some see the dip as oversold and are looking for a support bounce, while others remain cautious about further selling and earnings volatility.

Hewlett Packard Enterprise Co. is a global edge-to-cloud company, which engages in the provision of information technology, technology and enterprise products, solutions, and services. It operates through the following segments: Server, Hybrid Cloud, Intelligent Edge, Financial Services, and Corporate Investments and Other. The Server segment consists of general-purpose servers for multi-workload computing and workload-optimized servers to deliver the performance and value for demanding applications, and integrated systems comprised of software and hardware designed to address high-performance computing and supercomputing, artificial intelligence, data analytics, and transaction processing workloads for government and commercial customers globally. The Hybrid Cloud segment is involved in a variety of cloud-native and hybrid solutions across storage, private cloud, and the infrastructure software-as-a-service space. The Intelligent Edge segment offers wired and wireless local area networks, campus, branch, and data center switching, software-defined wide-area-networks, private and public cellular network software, network security, and associated services that enable secure connectivity for businesses of any size. The Financial Services segment provides investment solutions, such as leasing, financing, IT consumption, utility programs, and asset management services for customers that facilitate technology deployment models and the acquisition of complete IT solutions, including hardware, software, and services from Hewlett Packard Enterprise and others. The Corporate Investments and Other segment includes the Advisory and Professional Services business, which primarily offers consultative-led services, HPE and partner technology expertise and advice, implementation services, as well as complex solution engagement capabilities, the Communications and Media Solutions business, which primarily offers software and related services to the telecommunications industry, and Hewlett Packard Labs, which is responsible for research and development. The company was founded by William R. Hewlett and David Packard on July 2, 1939 and is headquartered in Spring, TX.

Hewlett Packard Enterprise Co

HPE is drawing attention after a sharp selloff alongside enterprise hardware peers, with traders pointing to Barclays downgrade and concerns that AI spending has not yet produced a meaningful growth inflection, while higher memory costs may also temper upside. The community is split between viewing the drop as an overreaction and buying opportunity and worrying that the stock may remain under pressure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The Next Big Thing Is Never on Time

From Tesla’s (NASDAQ:TSLA) rocket-powered Roadster to Xeriant’s (OTCQB:XERI) fire-resistant NexBoard, history’s biggest technological breakthroughs share a common pattern: years of skepticism, setbacks and painstaking development before the moment when the impossible starts looking inevitable.

Is Trending Stock Vertex Pharmaceuticals Incorporated (VRTX) a Buy Now?

Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts

Vertex Pharmaceuticals (VRTX) reached $508.75 at the closing of the latest trading day, reflecting a +2.06% change compared to its last close.

Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $510.08, marking a +1.36% move from the previous day.

Vertex to Present New Data on ALYFTREK at the North American Cystic Fibrosis Conference

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children...

If You Invested $100 In Vertex Pharmaceuticals Stock 5 Years Ago, You Would Have This Much Today

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 10.96% on an annualized basis producing an average annual return of 23.3%. Currently, Vertex Pharmaceuticals has a marketread more...

Vertex to Announce Third Quarter 2026 Financial Results November 2nd

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2026 financial results on Monday, November 2, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1...

Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains?

Novavax (NVAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know  

Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?

Key PointsAmgen offers a diversified portfolio of established therapies across oncology and inflammation supported by robust cash flow...

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Vertex Pharmaceuticals, Inc.

Twin Moves: VRTX Rises On Kidney Disease Trial Results, MAZE Rallies Harder  

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>In people with modest proteinuria, albumin in the urine fell 42.7% from baseline, and total protein fell 44.7% in the study.&nbsp;</li><li>A second group — people who also have type 2 diabetes — saw a smaller drop: 17.3% for albumin and 25.4% for total protein.</li><li>Truist called the data a validation of APOL1 inhibition in a potential market of more than 100,000 patients and said the opportunity is large enough to support blockbuster sales for Maze’s MZE829 even if it only matches inaxaplin.</li></ul><p><br>Shares of Vertex Pharmaceuticals (VRTX) rose 3% on Tuesday after the company said its experimental pill inaxaplin cut protein leakage into urine in a study in two extra groups of patients with APOL1-mediated kidney disease (AMKD), a genetic condition with no approved treatments.</p><p>Rival Maze Therapeutics (MAZE), which is developing its own drug for the condition called MZE829, jumped more sharply, by about 25%, on the read-through.</p><h2 class="st-heading-2">Broader Patients, Similar Signal</h2><p>The mid-stage AMPLIFIED study tested a once-daily 45 mg dose of inaxaplin for 13 weeks on top of optimized standard care. In people with modest proteinuria, urinary albumin fell 42.7% from baseline, and total protein fell 44.7%. That matched an earlier mid-stage study in patients with a scarring form of the disease known as Focal Segmental Glomerulosclerosis (FSGS). Most people in the new modest-proteinuria group did not have an FSGS diagnosis.</p><p>A second group — people who also have type 2 diabetes — saw a smaller drop: 17.3% for albumin and 25.4% for total protein. Vertex called that effect encouraging but more modest. The drug was generally well tolerated. No serious side effects were tied to inaxaplin; headache was the most common complaint.</p><p>AMKD is a rapidly progressing disease caused by two variants in the APOL1 gene and occurs mainly in people of African ancestry. Vertex estimates it affects about 150,000 people in the United States and Europe. Left untreated, it can lead to dialysis, transplant, or death.</p><h2 class="st-heading-2">Pivotal Study Now Fully Enrolled</h2><p>Vertex also said it has finished enrollment in AMPLITUDE, the larger trial in patients with more severe proteinuria and no other major kidney-damaging conditions. An interim look is due in early 2027 and, if positive, could support a U.S. accelerated-approval filing. The company plans to discuss the AMPLIFIED results with regulators alongside that program.</p><p>Chief medical officer Carmen Bozic said the findings add to evidence that inaxaplin could become a first- and best-in-class therapy aimed at the disease’s root cause.</p><h2 class="st-heading-2">Analysts See A Bigger Market — And A Lift For Maze</h2><p>Truist analyst Danielle Brill called the data a meaningful validation of APOL1 inhibition in classic AMKD and estimated an addressable population of more than 100,000 patients. Truist sees “a significant positive readthrough” for Maze. While it is too early to compare the two drugs, the firm said the opportunity is large enough to support blockbuster sales for MZE829 even if efficacy and safety prove only comparable to inaxaplin. Truist rates Maze a Buy with a $64 price target. The new price target implies a potential upside of about 186% from the stock’s last closing price on Monday.</p><h2 class="st-heading-2">How Did VRTX Retail Traders React?</h2><p>On Stocktwits, retail sentiment around VRTX stock stayed in ‘bearish’ territory over the past 24 hours, while message volume stayed ‘low.’</p><p>Meanwhile, sentiment around MAZE jumped from ‘neutral’ to ‘bullish’ over the past 24 hours, while retail chatter jumped to ‘high’ levels.</p><p><a href="https://stocktwits.com/symbol/VRTX">VRTX stock</a> is up about 15% year to date. <a href="https://stocktwits.com/symbol/MAZE">MAZE </a>is down about 35% over the same stretch, leaving Tuesday’s pop against a steep 2026 drawdown.</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/michael-burry-memory-stocks-thesis-gets-fresh-support-from-acer-ceo-supply-warning/cZMPMm7RB7b">Michael Burry’s Memory Stocks Thesis Gets Fresh Support From Acer CEO’s Supply Warning</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

In this photo illustration, Vertex Pharmaceuticals' logo is displayed on a smartphone screen in front of a stock chart. (Photo illustration by Cheng Xin/Getty Images)

Vertex on Tuesday announced results from the mid-stage trial of its experimental pill, inaxaplin, in two groups of patients with APOL1-mediated kidney disease.

Maze Therapeutics Inc.

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$501.95
Prev Close	$499.74
Open	$500.00
Dividend Yield	0.00%
50-Day Moving Average	$522.66
Beta	0.53
Avg. Volume	1.02M
PE Ratio	29.20

52-Week High	$560.25
52-Week Low	$403.16
Market Capitalization	$126.66B
EPS (Annual)	$15.32
Price to Book	6.28
Revenue Per Employee	$1.89M

Feed

News

Sentiment

Earnings

Fundamentals

Info

VRTX Fundamentals